Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
Conclusions
Our results showed that the substantially higher medication costs of rivaroxaban were offset by mitigating the shortcomings of warfarin, most notably frequent dose regulation and bleeding risk. Future health economic studies on novel oral anticoagulants should evaluate the cost effectiveness for secondary stroke prevention and, as clinical data from direct head-to-head comparisons become available, new anticoagulation therapies should be compared against each other.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Atrial Fibrillation | Bleeding | Coumadin | Health Insurance | Health Management | Hemorrhagic Stroke | Insurance | Stroke | Study | Warfarin